Болезнь Кастлемана (обзор литературы)
https://doi.org/10.17650/1818-8346-2016-11-2-8-20
Аннотация
Болезнь Кастлемана (ангиофолликулярная гиперплазия лимфатических узлов) – редкое доброкачественное лимфопролиферативное заболевание с длительным бессимптомным течением, ассоциированное с широким спектром аутоиммунных и онкологических заболеваний и риском развития неходжкинской лимфомы. Редкая встречаемость данного заболевания и разнообразие клинического течения не позволяют провести полноценные и последовательные исследования по изучению его этиологии и патогенеза, разработать стандартные методы терапии. В последние годы число пациентов с болезнью Кастлемана в Российской Федерации увеличилось, и это требует ее распознавания среди неопухолевых и опухолевых лимфаденопатий. Статья посвящена обзору данных о клинических и гистологических вариантах болезни Кастлемана, концепциях ее патогенеза, классификации и лечения.
Об авторах
А. Л. Меликян
ФГБУ «Гематологический научный центр» Минздрава России; Россия, 125167, Москва, Новый Зыковский проезд, 4а
Россия
Россия
Е. К. Егорова
ФГБУ «Гематологический научный центр» Минздрава России; Россия, 125167, Москва, Новый Зыковский проезд, 4а
Россия
Россия
Список литературы
1. Castleman B., Thowne V. W. Case records of the Massachusetts General Hospital Weekly Clinicopathological Exercises: Case 40011. New Engl J Med. 1954;250:26–30. DOI: 10.1056/NEJM195401072500107; PMID: 13111435.
2. Castleman B., Iverson L., Menendez V. P. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9(4):822– 30. DOI: 10.1002/1097–0142(195607/08) 9:4; PMID: 13356266.
3. Keller A. R., Hochholzer L., Castleman B. Hyaline-vascular and plasma cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972;29(3):670–83. DOI: 10.1002/1097–0142(197203) 29:3; PMID: 4551306.
4. Ioachim H. L. Castleman’s disease. In: Ioachim H. L., Howard R. Ioachims lymph node pathology. JB Lippinott Co, 2006.
5. Menke D. M., Tiemann M., Camoriano J. K. et al. Diagnosis of Castleman’s disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffinembedded lymph node biopsies. Am J Clin Pathol 1996;105(3):268– 76. DOI: 10.1093/ ajcp/105.3.268; PMID: 8602606.
6. Frizzera G. Castleman’s disease and related disorders. Semin Diagn Pathol 1988;5(4):346– 64. PMID: 2464187.
7. Меликян А. Л., Егорова Е. К., Ковригина А. М. и др. Клинико-морфологические особенности различных вариантов болезни Кастлемана. Терапевтический архив 2015;87(7):64–71 [Melikyan A. L., Egorova E. K., Kovrigina A. M. et al. Clinical and morphological features of different types of Castleman’s disease. Terapevticheskiy arkhiv = Therapeutic archives, 2015;87(7):64–71. (In Russ.)]. DOI:10.17116/ terarkh201587764-71; PMID: 26390727.
8. Dupin N., Diss T. L., Kellam P. et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95(4):1406–12. PMID:10666218.
9. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005;129(1):3–17. DOI: 10.1111/j. 1365– 2141.2004.05311. x; PMID: 15801951.
10. Kim J. E., Kim J. C., Park I. A. et al. Clinicopathologic study of Castleman’s disease in Korea. J Korean Med Sci 2000;15(4):393–8. DOI: 10.3346/jkms. 2000.15.4.393; PMID: 10983686.
11. Saeed-Abdul-Rahman I., Al-Amri A. M. Castleman disease. Korean J Hematol 2012;47(3):163–177. DOI: 10.5045/kjh. 2012.47.3.163; PMID: 23071471.
12. Cronin D. M., Warnke R. A. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009;16(4):236–246. DOI: 10.1097/ PAP. 0b013e3181a9d4d3; PMID: 19546611.
13. El-Osta H. E., Kurzrock R. Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist 2011;16(4):497– 511. DOI: 10.1634/theoncologist. 2010– 0212; PMID: 21441298.
14. Talat N., Schulte K. M. Castleman’s disease: systematic analysis of 416 patients from the literature. Oncologist 2011;16(9):1316–24. DOI: 10.1634/ theoncologist. 2011–0075; PMID: 21765191.
15. Soulier J., Grollet L., Oksenhendler E. et al. Molecular analysis of clonality in Castleman’s disease. Blood 1995;86(3):1131–8. PMID: 7620166. 16. Akira S., Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1–78. PMID: 8379461.
16. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010;22(5):347– 52. DOI: 10.1093/intimm/ dxq030; PMID: 20410258.
17. Skiniotis G., Boulanger M. J., Garcia K. C. et al. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat Struct Mol Biol 2005;12(6):545–51. DOI: 10.1038/nsmb941; PMID: 15895091.
18. Bataille R., Jourdan M., Zhang X. G. et al. IL-6 is a potent growth factor for plasma cells and is elevated in overt myeloma and plasma cell leukemia. J Clin Invest 1989:84:2008– 2011. DOI: 10.1172/ JCI114392; PMID: 2592570.
19. O’Shea J. J., Murray P. J. Cytokine signaling modules in inflammatory responses. mmunity 2008;28(4):477–87. DOI: 10.1016/j. immuni. 2008.03.002; PMID: 18400190.
20. Yoshizaki K., Matsuda T., Nishimoto N. et al. Pathogenic significance of interleukin- 6(IL- 6/BSF-2) in Castleman’s disease. Blood 1989:74(4):1360–7. PMID: 2788466.
21. Horii Y., Muraguchi A., Iwano M. et al. Involvement of interleukin-6 in mesangial proliferative glomerulonephritis. J Immunol 1989:143(12):3949–55. PMID: 2592764.
22. Miles S. A., Rezai A. R., Salazar-González J. F. et al. AIDS Kaposi sarcomaderived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990;87(11):4068–72. PMID: 1693429.
23. Leger-Ravet M. B., Peuchmaur M., Devergne O. et al. Interleukin-6 gene expression in Castleman’s disease. Blood 1991;78(11):2923–30. PMID: 1954381.
24. Van Rhee F., Fayad L., Voorhees P. et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol 2010;28(23):3701–8. DOI: 10.1200/JCO. 2009.27.2377; PMID: 20625121.
25. Nishimoto N., Terao K., Mima T. et al. Mechanisms and pathologic significances in increase in serum interleukin-6(IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112(10):3959–64. DOI: 10.1182/ blood-2008‑05‑155846; PMID: 18784373.
26. Corbellino M., Poirel L., Aubin J. T. et al. The role of human herpesvirus 8 and Epstein – Barr virus in the pathogenesis of giant lymph node hyperplasia(Castleman’s disease). Clin Infect Dis 1996;22(6):1120–1. DOI: 10.1093/clinids/22.6.1120; PMID: 8783733.
27. Chang Y., Cesarman E., Pessin M. S. et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994;266(5192):1865–9. DOI: 10.1126/science. 7997879; PMID: 7997879.
28. Orenstein J. M., Alkan S., Blauvelt A. et al. Visualization of human herpesvirus type 8 in Kaposi»s sarcoma by light and transmission electron microscopy. AIDS 1997;11(5):35–45. PMID: 9108935.
29. Renne R., Lagunoff M., Zhong W. et al. The size and conformation of Kaposi’s sarcoma- associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol 1996;70(11):8151–4. PMID: 8892944.
30. Hu J., Renne R. Characterization of the minimal replicator of Kaposi’s sarcoma- associated herpesvirus latent origin. J Virol 2005;79(4):2637–42. DOI: 10.1128/ JVI. 79.4.2637–2642.2005; PMID: 15681465.
31. Damania B. Oncogenic gammaherpesviruses: comparison of viral proteins involved in tumorigenesis. Nat Rev Microbiol 2004;2(8):656–68. DOI: 10.1038/ nrmicro958; PMID: 15263900.
32. Du M. Q., Bacon C. M., Isaacson P. G. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol 2007;60(12):1350–7. DOI: 10.1136/jcp. 2007.047969; PMID: 18042691.
33. Cai Q., Verma S. C., Lu J. et al. Molecular biology of Kaposi’s sarcoma herpesvirus and related oncogenesis. Adv Virus Res 2010;78:87–142. DOI: 10.1016/B978‑0‑12‑ 385032‑4.00003–3; PMID: 21040832.
34. Sakakibara S., Tosato G. Viral interleukin-6: role in Kaposi’s sarcomaassociated herpesvirus-associated malignancies. J Interferon Cytokine Res 2011;31(11):791–801. DOI: 10.1089/jir. 2011.0043; PMID: 21767154.
35. Foss H. D., Araujo I., Demel G. et al. Expression of vascular endothelial growth factor in lymphomas and Castleman’s disease. J Pathol 1997;183(1):44–50. DOI: 10.1002/(SICI) 1096– 9896(199709) 183:1; PMID: 9370946.
36. Menke D. M., Chadburn A., Cesarman E. et al. Analysis of the human herpesvirus 8 (HHV- 8) genome and HHV-8 vIL-6 expression in archival cases of castleman disease at low risk for HIV infection. Am J Clin Pathol 2002;117(2):268–75. DOI: 10.1309/7243-AV50-KJ28-V6J9; PMID: 11863223.
37. Foussat A., Fior R., Girard T. et al. Involvement of human interleukin-6 in systemic manifestations of human herpesvirus type 8 – associated multicentric Castleman’s disease. AIDS 1999;13(1):150– 2. PMID: 10207568.
38. Ko S. F., Hsieh M. J., Ng S. H. et al. Imaging spectrum of Castleman’s disease. AJR Am J Roentgenol. 2004;182(3):769–75. PMID: 14975984.
39. Reddy M. P., Graham M. M. FDG positron emission tomographic imaging of thoracic Castleman’s disease. Clin Nucl Med 2003;28(4):325–6. PMID: 12642717.
40. Меликян А. Л., Егорова Е. К., Карагулян С. Р. и др. Развитие опухоли из фолликулярных дендритных клеток при гиалино-васкулярном варианте болезни Кастлемана. Терапевтический архив 2009;7:75–77. [Melikyan A. L., Egorova E. K., Karagulyan S. R. et al. The development of follicular dendritic cells tumors in hyaline- vascular type of Castleman’s disease. Terapevticheskiy arkhiv = Therapeutic archives 2009;7:75–77 (In Russ.)].
41. Peterson B. A., Frizzera, G. Multicentric Castleman’s disease. Semin Oncol 1993;20(6):636–47. PMID: 8296200.
42. Suda T., Katano H., Delsol G. et al. HHV-8 infection status of AIDS-unrelated and AIDS- associated multicentric Castleman’s disease. Pathol Int 2001;51(9):671–9. DOI: 10.1046/j. 1440–1827.2001.01266. x; PMID: 11696169.
43. Belec L., Mohamed A. S., Authier F. J. et al. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman’s disease. Blood 1999:93(11):3643–53. PMID: 10339470.
44. Verbrugghe W., Maes B. D., Knockaert D. C. Localised plasma-cell type Castleman’s disease and AA-amyloidosis cured by resection. A case report and review of the literature. Acta Clin Belg 2005:60(1):22–7. DOI: 10.1179/acb. 2005.006; PMID: 15981701.
45. Haque S., van Kirk R. Three patients with both Hodgkin’s lymphoma and Castleman’s disease: Clinicopathologic correlations and lack of association with HHV-8. Indian J Med Paediatr Oncol 2009;30(2):76–9. DOI: 10.4103/0971–5851.60052; PMID: 20596307.
46. Dispenzieri A. POEMS syndrome. Blood 2007;21(6):285–99. DOI: 10.1016/j. blre. 2007.07.004; PMID: 17850941.
47. Kaplan L. D. Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. Hematology Am Soc Hematol Educ Program 2013;2013:103–8. DOI: 10.1182/asheducation-2013.1.103; PMID: 24319170.
48. Oksenhendler E., Duarte M., Soulier J. et al. Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996;10(1):61–7. PMID: 8924253.
49. Miranda F. A., Faria V. H., Arruda G. V. et al. Radiation therapy in the treatment of unicentric Castleman’s disease. J Bras Pneumol 2013;39(1):116–8. DOI: 10.1590/ S1806- 37132013000100019; PMID: 23503497.
50. Chronowski G. M., Ha C. S., Wilder R. B. et al. Treatment of unicentric and multicentr Castleman disease and the role of radiotherapy. Cancer 2001;92(3):670–6. PMID: 11505414.
51. Ogita M., Hoshino J., Sogawa Y. et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol 2007;68(3):171–6. PMID: 17915620.
52. Nord J. A., Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman’s disease. Int J STD AIDS 2003;14(1):61–2. PMID: 12590797.
53. Rieu P., Droz D., Gessain A., Grünfeld J. P., Hermine O. Retinoic acid for treatment of multicentric Castleman’s disease. Lancet 1999;354(9186):1262–3. DOI: 10.1016/ S0140– 6736(99) 03957–4; PMID: 10520638.
54. Lee F. C., Merchant S. H. Alleviation of systemic manifestations of multicentric Castleman’s disease by thalidomide. Am J Hematol 2003;73(1):48–53. DOI: 10.1002/ ajh. 10310; PMID: 12701121.
55. Gérard L., Bérezné A., Galicier L. et al. Prospective study of rituximab in chemotherapy- dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 Castleman B Trial. J Clin Oncol 2007;25(22):3350–3356. DOI: 10.1200/JCO. 2007.10.6732; PMID: 17664482.
56. Bower M., Powles T., Williams S. et al. Brief communication: Rituximab in HIVassociated multicentric Castleman disease. Ann Intern Med 2007;47(12): 836–9. DOI: 10.7326/0003‑4819‑147‑12‑200712180‑0000 3; PMID: 18087054.
57. Ocio E. M., Sanchez-Guijo F. M., Diez-Campelo M. et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol 2005;78(4):302–5. DOI: 10.1002/ajh. 20283; PMID: 15795923.
58. Beck J. T., Hsu S. M., Wijdenes J. et al. Brief report: Alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994;330:602–605. DOI: 10.1056/NEJM199403033300904; PMID: 8302342.
59. Nishimoto N., Kanakura Y., Aozasa K., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106(8);2627–32. DOI: 10.1182/blood-2004‑12‑460; PMID: 15998837.
60. Sobas M. A., Alonso Vence N., Dias Arias J. et al. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to POEMS syndrome(MCD-POEMS variant). Ann Hematol 2010:89(2):217–9. DOI: 10.1007/ s00277‑009‑0795‑6; PMID: 19636554.
61. Galeotti C., Tran T. A., Franchi-Abella S. et al. IL-1 RA Agonist(anakinra) in the treatment of multifocal Castleman disease: Case report. J Pediatr Hematol Oncol 2008;30:920–924. DOI: 10.1097/MPH. 0b013e31818ab31f; PMID:19131781.
62. El-Osta H., Janku F., Kurzrock R. Successful treatment of Castleman’s disease with interleukin-1 receptor antagonist (anakinra). Mol Cancer Ther 2010:9:1485– 1488. DOI: 10.1158/1535–7163. MCT-10- 0156; PMID: 20501803.
63. Casper C., Nichols W. G., Huang M. L. et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004;103(5):1632–1634. DOI: 10.1182/ blood-2003‑05‑1721; PMID: 14615380.
64. Berezne A., Agbalika F., Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 2004;103(11):4368–4369. DOI: 10.1182/ blood- 2004‑01‑0158; PMID: 15155471.
Рецензия
Для цитирования:
Меликян А.Л., Егорова Е.К. Болезнь Кастлемана (обзор литературы). Онкогематология. 2016;11(2):8-20. https://doi.org/10.17650/1818-8346-2016-11-2-8-20
For citation:
Melikyan A.L., Egorova E.K. Castleman disease (literature review). Oncohematology. 2016;11(2):8-20. (In Russ.) https://doi.org/10.17650/1818-8346-2016-11-2-8-20
Просмотров: 33706
Послать статью по эл. почте 